NeoPharm maintains Merrill's buy rating

Merrill Lynch analyst David Munno kept NeoPharm, Inc. at its buy rating but lowered the price target to $12 from $18 due to increased binary risk because it effectively put its pipeline programs, other than lead drug IL13, on clinical hold. Shares of the Lake Forest, Ill., biopharmaceutical company were down 49 cents, or 6.13%, at $7.50 on volume of 329,439 shares versus the three-month running average of 284,089 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.